Philippe de Saussure
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Bansky G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2010
22.12.2010Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
22.12.2010Inflamm Bowel Dis 2010
Vavricka Stephan R, Michetti Pierre, Straumann Alex, Seibold Frank, Scharl Michael, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Bansky Georg, Schoepfer Alain M, for the Swiss IBDnet
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory bowel diseases 2009
10.12.2009Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
10.12.2009Inflammatory bowel diseases 2009
Schoepfer Alain M, Straumann Alex, Seibold Frank, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Vavricka Stephan R, Michetti Pierre